Amgen's Phase III ASPIRE trial of myeloma treatment Kyprolis meets primary endpoint - Clinical Trials Arena
Second Phase 3 Study Shows KYPROLIS Regimen Improves Overall Survival in Patients with Relapsed MM | American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology
Cancers | Free Full-Text | Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma ( ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial - The Lancet Oncology
KRd vs Rd Study Results & Efficacy | KYPROLIS® (carfilzomib)
Frontiers | Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
Clinical Challenges in Patients With Relapsed/Refractory Multiple Myeloma (Transcript)
Phase 3 Studies Show Kyprolis (Carfilzomib) Extends Progression Free Survival for Relapsed/Refractory Myeloma - HealthTree for Myeloma
Carfilzomib in multiple myeloma
Amgen presents new data for Kyprolis in multiple myeloma at EHA
Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR | Leukemia
Cancers | Free Full-Text | Carfilzomib-Based Regimen and Cardiotoxicity in Multiple Myeloma: Incidence of Cardiovascular Events and Organ Damage in Carfilzomib-Dexamethasone versus Carfilzomib-Lenalidomide-Dexamethasone. A Real-Life Prospective Study
AMGEN at Kyprolis
Carfilzomib Benefits Outweigh Potential for Cardiac Toxicity in Relapsed/Refractory Myeloma
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | NEJM
Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis® ( carfilzomib) Over Velcade® (bortezomib) In Patients With Relapsed Multiple Myeloma
Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment | Blood Cancer Journal
Relapsed and Refractory Myeloma - ppt video online download
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial | PLOS Medicine
Carfilzomib lenalidomide & dex (KRd) | Int'l Myeloma Fn
PDF) Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials
PDF) Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: Secondary analysis from the phase 3 ASPIRE study
PDF) Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III
Efficacy and Safety of Carfilzomib, Lenalidomide and Dexamethasone in MM | Research To Practice
Final ASPIRE Results Confirm Survival Benefit With Carfilzomib Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma
Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma | Leukemia
Design of randomized phase 3 trials. A, ASPIRE trial; B, ENDEAVOR... | Download Scientific Diagram
